Inaktiver Wert

Andere Sprachen GRI Bio, Inc.

Aktien

GRI

US3622AW2059

GRI

Schlusskurs Nasdaq Andere Börsenplätze 00:00:00 15.05.2024			% 5 Tage	% 1. Jan.
0.4007 ^USD	-1.18%		+2.72%	-85.13%

21.05.	GRI Bio, Inc. präsentiert positive präklinische Daten aus der Pipeline der in der Entwicklung befindlichen NKT-Zell-Modulatoren für die Behandlung von systemischem Lupus erythematodes	CI
20.05.	GRI Bio, Inc. Präsentiert positive präklinische Daten, die zeigen, dass das Hauptprodukt GRI-0621 die wichtigen entzündlichen und fibrotischen Faktoren bei idiopathischer Lungenfibrose (IPF) reduziert	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus	21.05.
GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis	20.05.
GRI Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10.05.
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators with Issuance of Korea Patent	16.04.
GRI Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
GRI Bio, Inc. Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom	04.03.
GRI Bio's Board Approves 1-for-7 Reverse Stock Split to Regain Nasdaq Compliance	26.01.
GRI Bio Announces Reverse Stock Split	26.01.
GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment	06.12.
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	05.12.
GRI Bio, Inc. Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis	05.12.
GRI Bio Secures FDA Clearance for Investigational New Drug Application for Pulmonary Fibrosis Treatment	27.11.
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)	27.11.
GRI Bio, Inc. Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis	27.11.
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update	15.11.
GRI Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases	31.10.23
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference	19.10.23
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression	17.10.23
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference	11.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen GRI Bio, Inc.

Aktien

GRI

US3622AW2059

GRI

Andere Sprachen

Filter